Asia Fresh News

Asia Fresh Stories

Archive for December 2013

Prolexic Releases DDoS Protection Infographic: What to Look for in a DDoS Mitigation Provider Portal

leave a comment »

FORT LAUDERDALE, Fla., Dec. 30, 2013 /PRNewswire/ — Prolexic Technologies, the global leader in Distributed Denial of Service (DDoS) protection services, today released a DDoS protection infographic that provides guidance for evaluating the web portals offered by DDoS mitigation providers. The infographic can be viewed and downloaded at http://www.prolexic.com/ddosportal.
PLXportal Infographic
PLXportal Infographic
“Outdated information and limited customer visibility into a vendor’s DDoS mitigation efforts can increase downtime due to a DDoS attack,” said Stuart Scholly, president at Prolexic. “Web portals are a strategic decision-making tool, and businesses need to be rigorous in evaluating the offerings of DDoS mitigation providers.”
The DDoS mitigation portal infographic recommends that businesses focus on six key areas when evaluating a mitigation provider’s web portal:
Access from mobile devices
Log-in security
Data refresh rate
Network visibility
Real-time analytics
DDoS forensics and intelligence
According to Scholly, a high-quality web portal should play a critical role in DDoS mitigation vendor selection and DDoS defense. “A robust DDoS defense requires the mitigation provider and customer work together in a coordinated way. When the customer can see the same network and DDoS attack data as the mitigation provider at the same time, it allows for more informed decision making and faster mitigation,” he said.
Prolexic’s infographic, What to Look for in a DDoS Mitigation Provider Portal, can be viewed and downloaded at http://www.prolexic.com/ddosportal.
To take a video tour of PLXportal, Prolexic’s DDoS attack monitoring and mitigation customer portal, visit http://www.prolexic.com/plxportal.
About Prolexic
Prolexic is the world’s largest, most trusted Distributed Denial of Service (DDoS) mitigation provider. Able to absorb the largest and most complex attacks ever launched, Prolexic restores mission-critical Internet-facing infrastructures for global enterprises and government agencies within minutes. Ten of the world’s largest banks and the leading companies in e-Commerce, SaaS, payment processing, travel/hospitality, gaming, energy and other at-risk industries rely on Prolexic to protect their businesses. Founded in 2003 as the world’s first in-the-cloud DDoS mitigation platform, Prolexic is headquartered in Fort Lauderdale, Florida, and has scrubbing centers located in the Americas, Europe and Asia. To learn more about how Prolexic can stop DDoS attacks and protect your business, please visit http://www.prolexic.com, follow us on LinkedIn, Facebook, Google+, YouTube, and @Prolexic on Twitter.
Contact:
Michael E. Donner
SVP, Chief Marketing Officer
Prolexic
media {at} prolexic {dot} com
+1 (954) 620 6017
Source: Prolexic Technologies

Written by asiafreshnews

December 31, 2013 at 10:17 am

Posted in Uncategorized

Japan Shopping Festival Starting from 1st Dec

leave a comment »

Special Chinese New Year (CNY) 2014 activities to be held at Tokyo and Osaka
TOKYO, Dec. 27, 2013 /PRNewswire/ — The “Japan Shopping Festival” (http://www.gojsf.com) has commenced since 1 Dec 2013 to promote shopping and travelling in Japan, and is being held in Tokyo and Kansai region. Starting from 31 Jan 2014 (CNY), special “Japan Shopping Festival” activities for the CNY targeting overseas visitors will be held at Shinjuku and Ginza in Tokyo, and also in Osaka. Major CNY shopping highlights start from this event.
The
The “Japan Shopping Festival”(http://www.gojsf.com)has commenced since 1 Dec 2013 in Japan.
Special activities mainly include:
Major promotion at Shinjuku (31 Jan – 11 Feb) — Stores in Shinjuku will be providing convenient and high-quality services to overseas visitors, and prospective participating stores will be department stores, large grocery stores, and electronics stores. During this period, 80,000 copies of the “Shinjuku Shopping Guide” in five different languages will be available for tourists from overseas. Moreover, tourists can receive a first-ever “Handsfree Shopping” service from temporary booths set up in the shopping area. Your bags will be delivered to your hotels within the day.
“Special Treats Day” at the Ginza Mitsukoshi Store — CNY goody bags will be given out and prices of items are derived from a lucky number “8” which represents good fortune in Chinese.
CNY special activities in Kansai Mega Sales(31 Jan) — Department stores in Osaka on this day will offer special CNY goody bags to customers from abroad.
Special Tour to the Yebisu Beer Museum of Sapporo Breweries Limited (1 Feb) This tour is limited to just 20 lucky participants who can not only enjoy high-grade fresh Yebisu Beer available in Japan exclusively, but also are entitled toreceive limited edition souvenirs.
Source: Japan Shopping Festival

Written by asiafreshnews

December 30, 2013 at 4:21 pm

Posted in Uncategorized

Sovereign Accounting Thought Leader Symposium announced by Japonica Partners

leave a comment »

— Sovereign accounting will be one of the highest impact topics in 2014 —
FRANKFURT, Germany /PRNewswire/ — Japonica Partners (“Japonica”) announced today a global thought leader symposium titled “A New Era in Sovereign Accounting: Better Numbers, Better Performance”. Sovereign accounting will be one of the highest impact topics in 2014. The Symposium will take place in February 2014 in London and via closed webcast. The final date is to be announced.
The Symposium will feature two keynote speeches: (1.) “A New Era in Global Sovereign Accounting – Better numbers, better performance”, and (2.) “A New Era in Greece Sovereign Accounting – Adopting world-class accounting, publishing financial statements, returning to A+ borrowing costs, and creating extraordinary growth.”
Japonica commented:
“Both government officials and their constituencies must understand that we are in a new era in sovereign accounting where better numbers mean better performance.”
Additionally, there will be global thought leader discussion on the following eight topics:
1. Improving decision-making 2. Increasing accountability
3. Reflecting economic reality 4. Best-in-class financial statements
5. Adopting world-class accounting 6. Benefits to institutional investors
7. Rating agency responsibilities 8. Investment bank responsibilities
Japonica noted:
“For institutional sovereign bond investors, world-class sovereign financial statements are the bedrock of reducing investment risk and improving returns.”
The Symposium is one in a series of events supported by Japonica Partners as part of its “Greece is A+” campaign, which began in November with a full-page open letter and call-to-action in major publications worldwide to public policy makers in Athens, Brussels, Frankfurt, and Washington, D.C.
Japonica stated:
“Credit rating agencies and investment banks have a fiduciary responsibility to publicly advocate for and extensively analyze world-class sovereign financial statements.”
Symposium attendance is by invitation only. Interested parties may contact the lead organizer, Japonica Partners, for an invitation.
Japonica Partners is an entrepreneurial investment firm that makes concentrated investments in underperforming global special situations. Japonica is not a fund, nor does it provide investment advice.
Contact: Japonica Partners, Christopher Magarian, NewEra[@]Japonica.com, +1.401.861.6160
Source: Japonica Partners

Written by asiafreshnews

December 27, 2013 at 9:59 am

Posted in Uncategorized

Rotary announces president for 2015-16; first Sri Lankan ever to lead Rotary

leave a comment »

— Spearheaded Rotary’s recovery efforts in the aftermath of the 2004 Indian Ocean tsunami
EVANSTON, Illinois/PRNewswire/ — K.R. “Ravi” Ravindran, a business leader from Colombo, Sri Lanka, will be the 105thpresident of Rotary International – a global network of 1.2 million volunteers dedicated to tackling the world’s most pressing humanitarian challenges.
Ravindran, a member of the Rotary Club of Colombo, will begin his one-year term on 1 July 2015 as the first Sri Lankan to hold Rotary’s highest office. Ravindran says a top priority will be to strengthen clubs by attracting men and women committed to improving communities worldwide through volunteer service.
From supporting local food pantries to providing clean water in remote villages, Rotary clubs join forces to carry out impactful and sustainable projects at home and abroad. And Rotary members often are both first-responders and re-builders when major disasters strike, because Rotary clubs are present in every corner of the world.
After the devastation of the 2004 Indian Ocean tsunami, Ravindran led Rotary’s recovery efforts by helping to raise US$12 million to rebuild 22 schools, enabling nearly 15,000 children to resume their studies. “The tsunami could take away schools, homes, possessions, and even loved-ones, but it would never be allowed to take away the spirit of children,” said Ravindran.
Ravindran was also involved in many other tsunami-related projects in Sri Lanka, Indonesia, India, and Thailand that were supported by Rotary’s Solidarity in South Asia Fund for long term recovery. Rotary clubs around the world contributed nearly US$6 million to the fund. The projects include housing developments, orphanages, water and sanitation systems, solar oven technology, community-based credit unions, health centers, and the replacement of destroyed fishing trawlers.
As president, Ravindran will oversee Rotary’s top humanitarian goal of eradicating the paralyzing infectious disease polio. In 1988, Rotary helped launch the Global Polio Eradication Initiative with the WHO, UNICEF, and the U.S. Centers for Disease Control and Prevention. Since then, Rotary club members worldwide have contributed more than $1.2 billion and countless volunteer hours to the polio eradication effort.
Overall, the annual number of new polio cases has plummeted by more than 99 percent since the 1980s, when polio infected about 350,000 children a year. Only 223 new cases were recorded for all of 2012. More than two billion children have been immunized in 122 countries, preventing five million cases of paralysis and 250,000 deaths. Polio today remains endemic in only three countries, Afghanistan, Nigeria and Pakistan, although “imported” cases in previously polio-free areas – such as the Horn of Africa — will continue to occur until the virus is finally stopped in the endemic countries.
As Sri Lanka’s chair of Rotary’s polio eradication efforts, Ravindran led efforts to eradicate polio from Sri Lanka. His country became one of the first in Asia to become polio-free in Asia. The PolioPlus task force which he headed consisted of representatives from Rotary, UNICEF and the Sri Lankan government. The partnership successfully negotiated a ceasefire with the northern militants to allow polio immunizations to continue during scheduled National Immunization Days.
Ravindran is founder and CEO of Printcare PLC, a publicly listed company and global leader in the tea packaging industry. He also serves on the board of several other companies and charitable trusts. He is the founding president of the Sri Lanka Anti-Narcotics Association, the largest antinarcotics organization in Sri Lanka.
A Rotarian since 1974, Ravindran has served Rotary as a director and treasurer of Rotary International and as a trustee of The Rotary Foundation. He has been awarded The Rotary Foundation’s Citation for Meritorious Service and Distinguished Service Award and the Service Award for a Polio-Free World.
About Rotary
Rotary brings together a global network of volunteer leaders dedicated to tackling the world’s most pressing humanitarian challenges. Rotary connects 1.2 million members of more than 34,000 Rotary clubs in over 200 countries and geographical areas. Their work impacts lives at both the local and international levels, from helping families in need in their own communities to working toward a polio-free world. For more information, visit Rotary.org.
Source: Rotary International

Written by asiafreshnews

December 27, 2013 at 9:56 am

Posted in Uncategorized

European Commission Approves Update of Erbitux Metastatic Colorectal Cancer Labeling to Patients With RAS Wild-Type Tumors

leave a comment »

DARMSTADT, Germany, Dec. 23, 2013 /PRNewswire/ —
The European Commission’s approval is based on the CHMP positive opinion
Label update comes in response to new biomarker data obtained from the OPUS study
Merck Serono, the biopharmaceutical division of Merck, today announced that the European Commission has approved the Type II variation to amend the Erbitux® (cetuximab) product information, updating the indication for Erbitux to the treatment of patients with RAS wild-type metastatic colorectal cancer (mCRC). The approval of the European Commission follows the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) (issued in November 2013) and is based on the totality of data emerging on the role of mCRC RAS tumor status in the benefit-risk profile of the drug. The approval primarily refers to new biomarker data from the OPUS (OxaliPlatin and cetUximab in firSt-line treatment of mCRC) study.[1]
In recent analyses of studies evaluating monoclonal anti-epidermal growth factor receptor (EGFR) antibodies, such as Erbitux, tumor samples of patients with KRAS wild-type tumor status (exon 2) were assessed for additional RAS mutations (defined as mutations in exons 3 or 4 of KRAS and/or exons 2, 3 or 4 of NRAS). The results from these studies suggest that patients with RAS wild-type tumors may benefit from treatment with Erbitux, while patients with RAS mutant tumors may not.
“We fully endorse the update to the indication of Erbitux in metastatic colorectal cancer, as it will provide further guidance to physicians who manage patients with colorectal cancer,” said Belen Garijo, President and CEO of Merck Serono. “We will now be working with the regulatory agencies to effectively communicate the implications of this label change to healthcare professionals and patients.”
In the updated product information, Erbitux will now be indicated for the treatment of patients with EGFR-expressing, RAS wild-type mCRC in combination with irinotecan-based chemotherapy, in 1st line in combination with FOLFOX, or as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan. In this label change, the existing contraindication for the combination of Erbitux with oxaliplatin-containing chemotherapy is now extended to include patients with mutant RAS mCRC or for whom RAS mCRC status is unknown.
The full Erbitux patient information will be publicly available in the revised SmPC. Once updated, this will be available online at http://www.ema.europa.eu/ema
About the OPUS Study
OPUS is a randomized, controlled, Phase II trial, involving 337 mCRC patients, 179 with KRAS wild-type (exon 2) tumors, demonstrating the efficacy of Erbitux plus FOLFOX-4 (oxaliplatin-based therapy) versus FOLFOX-4 alone.[2] Results of a RAS tumor status analysis will be presented at Gastrointestinal Cancers Symposium (ASCO GI) in January 2014, in San Francisco, California, U.S..
About Colorectal Cancer
Colorectal cancer (CRC) is the fourth most common cancer worldwide, with an estimated incidence of more than 1.2 million cases globally.[3] An estimated 608,000 deaths from CRC occur worldwide each year, accounting for 8% of all cancer deaths and making it the fourth most common cause of death from cancer.[3] Almost 60% of the cases occur in developed regions, and incidence and mortality rates are substantially higher in men than in women.[3] In Europe alone, an estimated 436,000 people develop CRC every year, with approximately 212,000 people dying from the disease annually.[4]
References
1. Tejpar S, et al. Accepted at 2014 Gastrointestinal Cancers Symposium, January 16-18, 2014.
2. Bokemeyer C, et al. Ann Oncol 2011;22(7):1535-46.
3. Ferlay J, et al. Int J Cancer 2010;127(12):2893-917.
4. Ferlay J, et al. Eu J Cancer 2010;46(4):765-81.
For more information on Erbitux in colorectal and head & neck cancer, please visit http://www.globalcancernews.com.
About Erbitux
Erbitux® is a first-in-class and highly active IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR). As a monoclonal antibody, the mode of action of Erbitux is distinct from standard non-selective chemotherapy treatments in that it specifically targets and binds to the EGFR. This binding inhibits the activation of the receptor and the subsequent signal-transduction pathway, which results in reducing both the invasion of normal tissues by tumor cells and the spread of tumors to new sites. It is also believed to inhibit the ability of tumor cells to repair the damage caused by chemotherapy and radiotherapy and to inhibit the formation of new blood vessels inside tumors, which appears to lead to an overall suppression of tumor growth.
The most commonly reported side effect with Erbitux is an acne-like skin rash that seems to be correlated with a good response to therapy. In approximately 5% of patients, hypersensitivity reactions may occur during treatment with Erbitux; about half of these reactions are severe.
Erbitux has already obtained market authorization in over 90 countries for the treatment of colorectal cancer and for the treatment of squamous cell carcinoma of the head and neck (SCCHN).
Merck licensed the right to market Erbitux outside the U.S. and Canada from ImClone LLC, a wholly-owned subsidiary of Eli Lilly and Company, in 1998. In Japan, ImClone, Bristol-Myers Squibb Company and Merck jointly develop and commercialize Erbitux. Merck has an ongoing commitment to the advancement of oncology treatment and is currently investigating novel therapies in highly targeted areas.
About Merck Serono
Merck Serono is the biopharmaceutical division of Merck. With headquarters in Darmstadt, Germany, Merck Serono offers leading brands in 150 countries to help patients with cancer, multiple sclerosis, infertility, endocrine and metabolic disorders as well as cardiovascular diseases. In the United States and Canada, EMD Serono operates as a separately incorporated subsidiary of Merck Serono.
Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. We have an enduring commitment to deliver novel therapies in our core focus areas of neurology, oncology, immuno-oncology and immunology.
For more information, please visit http://www.merckserono.com.
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
Merck is a leading pharmaceutical, chemical and life science company with total revenues of EUR 11.2 billion in 2012, a history that began in 1668, and a future shaped by approx. 38,000 employees in 66 countries. Its success is characterized by innovations from entrepreneurial employees. Merck’s operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.
Contact:
Paul Olaniran
Phone +49(0)6151-72-2274
Source: Merck Serono

Written by asiafreshnews

December 24, 2013 at 10:54 am

Posted in Uncategorized

DPI Vendors Make Their Move Into SDN/NFV, Heavy Reading Finds

leave a comment »

DPI vendors are looking to SDN and NFV to boost network performance, says Heavy Reading Components Insider
NEW YORK /PRNewswire/ — Providers of DPI (deep packet inspection) technologies are shifting their focus to emerging software-defined network (SDN) and network functions virtualization (NFV) in an effort to boost network performance, according to the latest report from Heavy Reading Components Insider (www.heavyreading.com/commchip), a paid research service of Heavy Reading (www.heavyreading.com).
DPI Vendors Deliver on Policy Management & Analytics details and analyzes leading deep packet inspection (DPI), policy management and analytics system vendors, DPI and multicore processor vendors, and DPI and policy management software vendors. The report profiles 20 vendors in this important market, including a review of component architectures, identifying the key features and highlighting the advantages they hold for equipment manufacturers.
For a complete list of companies covered in this report, click here.
“Wireless and fixed line carriers are making significant investments in policy management and analytics,” says Simon Stanley, research analyst for Heavy Reading Components Insider and author of the report. “Policy management solutions enable carriers to efficiently manage their networks, making maximum use of their network infrastructure and deliver services that match the expectations of their subscribers.”
As data traffic on both wireless and fixed networks has grown, carriers have been forced to invest in DPI solutions for policy management and other functions, Stanley says. “Service provider DPI product revenue totaled $596 million worldwide in 2012, up 28 percent,” he adds. “The vendors that will be most successful going forward are those that can deliver DPI, policy management and analytics solutions that achieve 100Gbit/s performance in virtualized environments, including software-defined networking (SDN) and network functions virtualization (NFV).”
Key findings of DPI Vendors Deliver on Policy Management & Analytics include the following:
SDN/NFV are driving a shift to virtualized platforms running on standard servers or dedicated hardware
Strong ecosystem for DPI, policy management and analytics, including systems, software and processors
Long Term Evolution (LTE) remains a leading driver for growth in policy management and analytics
Consolidation in the market with Cisco, Intel and Procera acquiring key software suppliers
Intel x86 dominates the market, with vendors using bladed servers, ATCA platforms and virtualized architectures
ARMv8 based multicore processors entering market for DPI and microservers
Multicore processors with integrated hardware engines to support pattern matching for DPI applications
DPI Vendors Deliver on Policy Management & Analytics is available as part of an annual single-user subscription (6 issues per year) to Heavy Reading Components Insider, priced at $1,595. Individual reports are available for $900 (single-user license).
For more information about Heavy Reading Components Insider, please visit: http://www.heavyreading.com/commchip. For more information about other Heavy Reading Insider research services, please visit: http://www.heavyreading.com/research.
To request a free executive summary of the report, or for details on multi-user licensing options, please contact:
David Williams
Global Director of Sales, Research
Heavy Reading
+1-858-829-8612
david.williams@ubm.com
Press/analyst contact:
Dennis Mendyk
Vice President of Research, Heavy Reading
+1-201-587-2154
mendyk@heavyreading.com
About Heavy Reading (www.heavyreading.com)
Heavy Reading is an independent research organization offering deep analysis of emerging telecom trends to network operators, technology suppliers, and investors. Its product portfolio includes in-depth reports that address critical next-generation technology and service issues, market trackers that focus on the telecom industry’s most critical technology sectors, exclusive worldwide surveys of network operator decision-makers that identify future purchasing and deployment plans, and a rich array of custom and consulting services that give clients the market intelligence needed to compete successfully in the global telecom industry. As a division of UBM Tech (tech.ubm.com), Heavy Reading contributes to the only integrated business information platform serving the global communications industry.
Source: Heavy Reading

Written by asiafreshnews

December 23, 2013 at 10:05 am

Posted in Uncategorized

Monetization Ideas Bring Policy Management Market Evolution, Heavy Reading Finds

leave a comment »

— The policy management market has changed over the last few years due to CSPs’ new monetization tactics, says Heavy Reading Service Provider IT Insider
NEW YORK, Dec. 20, 2013 /PRNewswire/ — Communication service providers (CSPs) are pursuing new monetization strategies in the policy management market, causing the market to drastically change over the last few years, according to the latest report from Heavy Reading Service Provider IT Insider (www.heavyreading.com/servsoftware), a subscription research service from Heavy Reading(www.heavyreading.com).
Smart Data Monetization: Operator Strategies Take Shape analyzes the role that policy management will play in network operator data monetization efforts. It looks at the potential for policy management to serve as a cooperative platform for network and IT departments to collaborate. The report also assesses different business drivers for using policy management in data monetization initiatives. It includes results from an exclusive Heavy Reading survey of network operators regarding their deployment strategies regarding policy management and charging.
“The policy management market has undergone radical transformation in the last few years,” says Ari Banerjee, research analyst with Heavy Reading Service Provider IT Insider and author of the report. “The evolution of policy management and the change in the manner in which policy management solutions are now being deployed have a lot to do with how CSPs are rethinking their revenue monetization strategies.”
As CSPs continue to feel the data crunch on their networks, it is very possible for them to manage the copious amounts of data while also creating monetization, Banerjee says. “The fact that the majority of CSPs expect to change their rate plans and/or introduce new monetization policies as many as two to three times a year indicates that a highly agile solution will be needed to enable such goals,” he continues. “CSPs will be smart to align with a vendor that will be able to provide a flexible solution that will enable a manageable environment and allow for quick time-to-market for new services and products.”
Key findings of Smart Data Monetization: Operator Strategies Take Shape include the following:
Leveraging real-time, policy-driven solutions will provide operators with tools to differentiate their services, be more creative in their service offerings and distribute and control network resources more effectively
End-to-end policy deployment requires network and IT convergence
Policy decisions are being made jointly by network, IT and marketing, with marketing emerging as a key influencer group
Expect more market consolidation in the next six to 12 months
Emerging markets seem more advanced with more simple segmented plans while developed markets seem more aggressive with their plans for advanced segmented plans
Smart Data Monetization: Operator Strategies Take Shape is available as part of an annual single-user subscription (six issues) to Heavy Reading Service Provider IT Insider, priced at $1,595. Individual reports are available for $900 (single-user license).
To subscribe, or for more information, please visit: http://www.heavyreading.com/servsoftware. For more information about other Heavy Reading Insider research services, please visit: http://www.heavyreading.com/research.
To request a free executive summary of the report, or for details on multi-user licensing options, please contact:
David Williams
Global Director of Sales, Research
Heavy Reading
858-829-8612
david.williams@ubm.com
Press/analyst contact:
Dennis Mendyk
Vice President of Research, Heavy Reading
201-587-2154
mendyk@heavyreading.com
About Heavy Reading (www.heavyreading.com)
Heavy Reading is an independent research organization offering deep analysis of emerging telecom trends to network operators, technology suppliers, and investors. Its product portfolio includes in-depth reports that address critical next-generation technology and service issues, market trackers that focus on the telecom industry’s most critical technology sectors, exclusive worldwide surveys of network operator decision-makers that identify future purchasing and deployment plans, and a rich array of custom and consulting services that give clients the market intelligence needed to compete successfully in the global telecom industry. As a division of UBM Tech (tech.ubm.com), Heavy Reading contributes to the only integrated business information platform serving the global communications industry.
Source: Heavy Reading

Written by asiafreshnews

December 23, 2013 at 9:50 am

Posted in Uncategorized

Sydney Welcomes New Airline Service from Western China

leave a comment »

SYDNEY /PRNewswire/ — Sichuan Airlines’ first Chengdu-Chongqing-Sydney service, a new route which offers visitors from Western China direct access to Sydney, Australia, landed at Sydney Airport today.
Dignitaries from Sichuan Airlines joined CEO of Destination New South Wales Sandra Chipchase, CEO of Sydney Airport Kerrie Mather, and NSW Minister Victor Dominello, for the airline’s inaugural Chengdu-Chongqing-Sydney flight, a new route which will provide visitors from Western China with direct access to New South Wales and Sydney.
Dignitaries from Sichuan Airlines joined CEO of Destination New South Wales Sandra Chipchase, CEO of Sydney Airport Kerrie Mather, and NSW Minister Victor Dominello, for the airline’s inaugural Chengdu-Chongqing-Sydney flight, a new route which will provide visitors from Western China with direct access to New South Wales and Sydney.
Sichuan Airlines is a new service for Sydney and New South Wales, which will provide two flights per week on its Airbus A330-200 aircraft and 50,000 seats annually. Sydney Airport estimates this will bring around AUD 36.5 million in visitor expenditure to the NSW economy each year.
New South Wales Minister for Citizenship and Communities, Mr Victor Dominello, welcomed the inaugural flight, saying this extra service on a key route would offer great benefits for passengers from Western China to get to Australia’s most popular tourism destination, Sydney.
“This is another vote of confidence in Sydney as the tourist destination of choice for Chinese visitors,” Mr Dominello said.
The new Sichuan Airlines service supports recent findings from the International Visitor Survey, for the year to September 2013, which shows China remain the top source market of visitors to Sydney and NSW.
NSW is Australia’s number one state for Chinese tourism, attracting 61.1 per cent of all Chinese tourists who visit the country. We also have strong cultural ties — there are over 156,000 Chinese-born people who call NSW home.
“China now ranks as the largest international contributor of visitor nights and expenditure in NSW. For the year ending September 2013, a 13.8 per cent increase saw 413,000 visitors to NSW from China, which contributed AUD 1.38 billion to the State’s economy,” Mr Dominello said.
New South Wales Minister for Tourism and Major Events, Mr George Souris, said the new Sichuan Airlines service linking Chengdu, Chongqing and Sydney will generate new tourism and business opportunities for NSW.
“Western China is one of the most exciting growth markets in China for NSW tourism and Sichuan Airlines’ decision to increase flights to Sydney will support this growth.
“Strong growth in Chinese visitors to NSW is proof the NSW Government’s China Tourism Strategy to increase visitor numbers from China is working. The strategy has been funded by the NSW Government to the tune of AUD 15 million over the next four years,” Mr Souris said.
Source: Destination NSW

Written by asiafreshnews

December 23, 2013 at 9:23 am

Posted in Uncategorized

Singaporeans Flocked to The Melaka Art & Performance Festival

leave a comment »

Over 50 artists from 10 countries participated in the largest festival at a UNESCO World Heritage Site

KUALA LUMPUR, Malaysia, Dec. 19, 2013 /PRNewswire/ — Thousands of Singaporeans recently visited the 5th Melaka Art & Performance Festival (MAPFest), the largest and only site specific art and performance festival on a UNESCO World Heritage Site, with art installations and performances by more than 50 renowned artists from 10 countries.
Eulogy of the Living, a haunting piece of performance art, which marked the closing of MAPFest 2013.
Eulogy of the Living, a haunting piece of performance art, which marked the closing of MAPFest 2013.

Andrew Ching, Founder and Producer of MAPFest said, “Over the years, MAPFest has become a yearly excursion for Singaporeans. The festival is widely supported and appreciated by Singaporeans and I expect it to only grow bigger.”

Artists from Australia, France, Indonesia, Ireland, Italy, Malaysia, the Netherlands, Poland, South Korea and Thailand used the historic city as their canvas, and the streets came alive with magnificent images and performances.

MAPFest is an innovative contemporary festival featuring dance, performance art, visual art, film and music. The festival throws the spotlight on Melaka’s famous heritage sites, and its collective ancestral heritage, to create a space for contemporary culture and artistic practice.

According to the festival organiser, the event attracted approximately 25,000 attendees, 5,000 of which were estimated to be from Singapore.

For the first time since its inception in 2009, MAPFest kicked off a new sister festival in Australia: Mapping Melbourne — Asian Contemporary Arts Festival (Australia).

Through the years, MAPFest has increased its international status, being recognised for its programme of exciting independent artists, collaborations and its use of alternative sites for performance.

Conceived and directed by Cheryl Stock, “Naik Naik” was the opening performance and also one of the highlight at MAPFest 2013. The festival kept it new with specialty components such as the “Cerita Pendek” (Short Stories), visual arts and discussions, as well as workshops. MAPFest 2013 culminating with “Eulogy for The Living”, a spectacular and soulful finale to the festival directed by Tony Yap, Founder and Creative Director of MAPFest.

MAPFest 2013 was produced by Arts & Performance Festival Melaka Sdn Bhd together with the efforts of E-Plus Entertainment, the Australian Government, High Commission of Australia, Australia Malaysia Institute, Multicultural Arts Victoria, Tony Yap Company, Mercatus+ Malaysia, Asialink, the Embassies of France, Thailand and Indonesia, the High Commission of Ireland, and the Malaysian National Department for Culture and Arts (JKKN).

For more information on MAPFest, visit http://www.melakafestival.com.
Source: Mercatus Plus (Malaysia) Sdn Bhd

Written by asiafreshnews

December 21, 2013 at 12:32 am

Posted in Uncategorized

Daiichi Sankyo Submits Supplemental New Drug Application in Japan for LIXIANA(R) (Edoxaban Tosilate Hydrate) for New Indications

leave a comment »

— Submission based on the two largest comparative phase 3 clinical trials of a novel oral anticoagulant in patients with non-valvular atrial fibrillation or symptomatic venous thromboembolism

— Regulatory filings for once-daily edoxaban planned by Q1 2014 in the U.S. and Europe

TOKYO, Dec. 19, 2013 /PRNewswire/ — Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has submitted a supplemental New Drug Application (NDA) for its oral, once-daily direct factor Xa-inhibitor LIXIANA® (Edoxaban Tosilate Hydrate) for review by the Japanese Ministry of Health, Labour and Welfare. Daiichi Sankyo is seeking approval in Japan for edoxaban in new indications for non-valvular atrial fibrillation (AF) and symptomatic venous thromboembolism (VTE).

The supplemental NDA submission is based on data from an extensive global clinical trial program that compared treatment with once-daily edoxaban to warfarin, a current standard of care for patients with AF or VTE. The two clinical trials that formed the basis of the submission, ENGAGE AF-TIMI 48 and Hokusai-VTE, are the largest comparative trials of a novel oral anticoagulant in these patient populations, involving 21,105 and 8,292 patients, respectively.1,2

“The submission of our supplemental NDA in Japan for edoxaban represents our long standing commitment to addressing the needs of patients living with cardiovascular diseases, including those living with atrial fibrillation or venous thromboembolism,” said Glenn Gormley, MD, PhD, Senior Executive Officer and Global Head of Research and Development, Daiichi Sankyo Co., Ltd. and President and CEO of Daiichi Sankyo, Inc. in the United States. “We look forward to working with the Japanese Ministry of Health, Labour and Welfare throughout its review of these new indications for edoxaban. Additionally, we plan to submit applications for edoxaban in the U.S. and Europe by the first quarter of 2014.”

About Edoxaban
Edoxaban is an investigational, oral, once-daily anticoagulant that specifically inhibits factor Xa, which is an important factor in the coagulation system that leads to blood clotting.3 The global edoxaban clinical trial program includes two phase 3 clinical studies, Hokusai-VTE and ENGAGE AF-TIMI 48 (Effective aNticoaGulation with Factor XA Next GEneration in Atrial Fibrillation). The results from these trials form the basis of the supplemental NDAs for edoxaban for symptomatic VTE in patients with deep vein thrombosis (DVT) and/or pulmonary embolism (PE), and for non-valvular AF, respectively.

Edoxaban is currently approved only in Japan, since April 2011, for the prevention of VTE after major orthopedic surgery, and was launched in July 2011 under the brand name LIXIANA®. Elsewhere, including Europe and the U.S., edoxaban is currently in phase 3 clinical development and has not been approved in any indication.4

About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a “Hybrid Business Model,” which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit: http://www.daiichisankyo.com.

Contact
Michaela Paudler-Debus, PhD
Daiichi Sankyo Europe
michaela.paudler-debus@daiichi-sankyo.eu
+49-89-7808-685 (office)
+49-176-11780966 (mobile)

Forward-looking statements
This press release contains forward-looking statements and information about future developments in the sector, and the legal and business conditions of DAIICHI SANKYO, Co. Ltd. Such forward-looking statements are uncertain and are subject at all times to the risks of change, particularly to the usual risks faced by a global pharmaceutical company, including the impact of the prices for products and raw materials, medication safety, changes in exchange rates, government regulations, employee relations, taxes, political instability and terrorism as well as the results of independent demands and governmental inquiries that affect the affairs of the company. All forward-looking statements contained in this release hold true as of the date of publication. They do not represent any guarantee of future performance. Actual events and developments could differ materially from the forward-looking statements that are explicitly expressed or implied in these statements. DAIICHI SANKYO, Co. Ltd assume no responsibility for the updating of such forward-looking statements about future developments of the sector, legal and business conditions and the company.

References

Giugliano, R et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2013;369:2093-2104.
Buller, H et al. Edoxaban versus Warfarin for the treatment of Symptomatic Venous Thromboembolism. N Engl J Med 2013;369:1406-1415.
Ogata, K et al. Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers. J Clin Pharmacol 2010;50:743-753.
Daiichi Sankyo press release – Daiichi Sankyo Launches LIXIANA® (edoxaban), a Direct Oral Factor Xa Inhibitor, in Japan for the Prevention of Venous Thromboembolism after Major Orthopaedic Surgery. 19 July 2011. Available at: http://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/005784.html. [Last accessed: December 2013].

Source: Daiichi Sankyo Company, Limited

Written by asiafreshnews

December 21, 2013 at 12:14 am

Posted in Uncategorized